Once again, the first-generation CD30-specific Mab HRS-3 turned out to be the most optimal candidate based on its high tumor antigen affinity (Kd 15 nM) and high activity as measured by inhibition of protein synthesis of L540 cHL cells by 50% [0.9 × 10(−10) M]. Here, TNFRSF8 is linked to neoplasm.